chemotherapy breast cancer – PubMed Results
- NCCN 2009: Guidelines for Breast Cancer Updated ( Medscape,Nick Mulcahy,19.3.2009)
- Changes Regarding Radiation Therapy -…The revision is based in part on a large EORTC study, which indicated that the boost did not provide a significant advantage in preventing recurrence over 8 years for women older than 60 years. However, the advantage was „highly significant“ in women younger than 40, said Dr. McCormick. She also noted there was some advantage to the boost in women aged 41 to 50 years and 51 to 60 years, but it was not as dramatic as it was for the young women. Hence, the guidelines present the boost as optional now, she said…
- Surgery for Women Who Present With Metastatic Disease….These women may benefit from the performance of local breast surgery and/or radiation therapy…Generally, this palliative local therapy should be considered only after response to initial systemic treatment…..In women who are left with clear margins, this approach doubles the median survival time to about 2 years, compared with 12 months in women who have no surgery.
- Adjuvant Therapy and Breast Reconstruction
…In its section on adjuvant chemotherapy, the NCCN’s breast cancer guidelines now rank the therapies. …For women who are not treated with trastuzumab (Herceptin, Genentech) regimens, the preferred regimens are:
TAC (docetaxel [Taxotere] plus doxorubicin [Adriamycin] plus cyclophosphamide);
dose-dense AC (doxorubicin plus cyclophosphamide) followed by paclitaxel every 2 weeks;
TC (docetaxel plus cyclophosphamide);
AC (doxorubicin plus cyclophosphamide).
For women who are treated with trastuzumab, the preferred adjuvant regimens are:
AC (doxorubicin plus cyclophosphamide) followed by T (docetaxel) plus concurrent trastuzumab;
TCH (docetaxel, carboplatin, trastuzumab)